SCHEMBL7523481

SCHEMBL7523481

CCOC(=O)CCCOc1cccc2c1CCC2=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.64
GAA P10253 1/20 0.64
BRD4 O60885 1/20 0.57
ABCB1 P08183 2/20 0.45
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MRGPRX4 Q96LA9 1/20 0.42
HTT P42858 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
LTB4R Q15722 3/20 0.41
LTB4R2 Q9NPC1 3/20 0.41
PDK2 Q15119 1/20 0.41
ADRB2 P07550 1/20 0.40
ADRB1 P08588 1/20 0.40
HTR1A P08908 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7519686 0.94 ALDH1A1 (0.65) ALDH1A1GAABRD4ABCB1L3MBTL1
SCHEMBL7525616 0.86 ALDH1A1 (0.56) ALDH1A1GAABRD4ABCB1MRGPRX4
SCHEMBL8460122 0.83 LTB4R (0.49) ALDH1A1GAAABCB1MRGPRX4LTB4R
SCHEMBL11127019 0.81 ABCB1 (0.53) ALDH1A1GAAABCB1L3MBTL1MRGPRX4
SCHEMBL11601503 0.80 DRD2 (0.52) ALDH1A1GAABRD4TDP1L3MBTL1
SCHEMBL7523415 0.80 PDE4A (0.44) ALDH1A1GAABRD4TDP1L3MBTL1
SCHEMBL4817908 0.80 ABCB1 (0.50) ALDH1A1GAAABCB1MRGPRX4HTT
SCHEMBL24510647 0.79 ABCB1 (0.52) ALDH1A1GAAABCB1TDP1L3MBTL1
SCHEMBL11285612 0.79 LOXL2 (0.46) ALDH1A1GAABRD4TDP1L3MBTL1
SCHEMBL7528817 0.79 ABCB1 (0.50) ALDH1A1GAAABCB1MRGPRX4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6417213-B2 ANTICOAGULANTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-07-09 US disclosed
US-20020006944-A1 Tricyclic compounds, their production and use OHKAWA SHIGENORI (JP) 2002-01-17 US disclosed
US-6248766-B1 CARDIOVASCULAR DISORDERS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-06-19 US disclosed
EP-0929534-A1 TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS Takeda Pharmaceutical Company Limited (JP) 1999-07-21 EP disclosed
WO-1998013356-A1 TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006944-A1 Tricyclic compounds, their production and use CNR1, PTGER1, PTGDR ALDH1A1 1662/4885GAA 4866/4885BRD4 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.